Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4292
Source ID: NCT00316758
Associated Drug: Gk Activator (2)
Title: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG: GK Activator (2)|DRUG: Metformin
Outcome Measures: Primary: AEs, laboratory parameters, ECG., Throughout study | Secondary: Mean change from original baseline in HbA1c, FPG, lipid profile., Throughout study
Sponsor/Collaborators: Sponsor: Hoffmann-La Roche
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 259
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2006-02
Completion Date: 2007-10
Results First Posted:
Last Update Posted: 2016-11-02
Locations: Chula Vista, California, 91910, United States|Chula Vista, California, 91911, United States|Los Angeles, California, 90057, United States|Spring Valley, California, 91978, United States|West Hills, California, 91307, United States|Hollywood, Florida, 33021, United States|Kissimmee, Florida, 34741, United States|Atlanta, Georgia, 30308, United States|Arkansas City, Kansas, 67005, United States|Butte, Montana, 59701, United States|Binghamton, New York, 13901, United States|Fayetteville, North Carolina, 28304, United States|Statesville, North Carolina, 28625, United States|Winston-salem, North Carolina, 27103, United States|Springdale, Ohio, 45246, United States|Oklahoma City, Oklahoma, 73112, United States|Medford, Oregon, 97504, United States|Beaver, Pennsylvania, 15009, United States|Mount Pleasant, South Carolina, 29464, United States|Memphis, Tennessee, 38119, United States|Federal Way, Washington, 98003, United States|Renton, Washington, 98055, United States|Camperdown, 2050, Australia|Heidelberg, 3081, Australia|Dimitrovgrad, 6400, Bulgaria|Pleven, 5800, Bulgaria|Ruse, 7002, Bulgaria|Sofia, 1233, Bulgaria|Sofia, 1606, Bulgaria|Vancouver, British Columbia, V5Z 1M9, Canada|London, Ontario, NGA 4V2, Canada|Montreal, Quebec, H1T 2M4, Canada|Zagreb, 10000, Croatia|Bammental, 69245, Germany|Berlin, 10115, Germany|Essen, 45355, Germany|Giessen, 35385, Germany|Görlitz, 02826, Germany|Hamburg, 20249, Germany|Kuenzing, 94550, Germany|Nürnberg, 90402, Germany|Tann, 36142, Germany|Guatemala City, 01015, Guatemala|Budapest, 1083, Hungary|Gyor, 9024, Hungary|Kecskemet, 6000, Hungary|Chihuahua, 31238, Mexico|Cuernavaca, 62270, Mexico|Durango, 34070, Mexico|Mexico City, 11650, Mexico|Mexico City, 14050, Mexico|Mexico City, 14610, Mexico|Mexico-city, 06700, Mexico|Bialystok, 15-276, Poland|Gdansk, 80-757, Poland|Gorzow, 66-400, Poland|Krakow, 31-121, Poland|Wroclaw, 50-088, Poland
URL: https://clinicaltrials.gov/show/NCT00316758

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D089 Metformin small molecule DB00331 Details